{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:32:17Z","timestamp":1793302337634,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12015-026-11236-z","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:44:46Z","timestamp":1789368286000},"page":"3670-3691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal Stem Cell Therapy for Systemic Sclerosis: Current Evidence and Clinical Applications"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-2754","authenticated-orcid":false,"given":"Umm E","family":"Habiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6226-2659","authenticated-orcid":false,"given":"Iqra","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0954-1480","authenticated-orcid":false,"given":"David Lawrence","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-3646","authenticated-orcid":false,"given":"Sabiha","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5543-1820","authenticated-orcid":false,"given":"Ammar","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"11236_CR1","volume-title":"Systemic Sclerosis (Scleroderma)[Updated 2024 Apr 5]","author":"R Adigun","year":"2025","unstructured":"Adigun, R., Goyal, A., & Hariz, A. (2025). Systemic Sclerosis (Scleroderma)[Updated 2024 Apr 5]. StatPearls Publishing."},{"key":"11236_CR2","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-022-00366-0","volume":"27","author":"M Al-Azab","year":"2022","unstructured":"Al-Azab, M., Safi, M., Idiiatullina, E., Al-Shaebi, F., & Zaky, M. Y. (2022). Aging of mesenchymal stem cell: Machinery, markers, and strategies of fighting. Cellular & Molecular Biology Letters,27, Article 69.","journal-title":"Cellular & Molecular Biology Letters"},{"key":"11236_CR3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10067-024-06865-z","volume":"43","author":"M Alip","year":"2024","unstructured":"Alip, M., Wang, D., Zhao, S., Li, S., Zhang, D., Duan, X., Wang, S., Hua, B., Wang, H., Zhang, H., Feng, X., & Sun, L. (2024). Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: A 5-year follow-up study. Clinical Rheumatology,43, 1073\u20131082.","journal-title":"Clinical Rheumatology"},{"key":"11236_CR4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1633845","volume":"16","author":"G Almanzar","year":"2025","unstructured":"Almanzar, G., Alarcon, J. C., Garzon, R., Navarro, A. M., Ondo-Mendez, A., & Prelog, M. (2025). Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - A link between cancer and autoimmunity. Frontiers in Immunology,16, Article 1633845.","journal-title":"Frontiers in Immunology"},{"key":"11236_CR5","volume":"16","author":"T Azad","year":"2025","unstructured":"Azad, T., Wu, F., Mao, J., Zhu, J., Wang, Y., Zhou, X., Hong, K., Xie, H., Qiu, X., Li, B., Zhang, L., Tian, J., & Wen, C. (2025). Exploring the therapeutic potential of MSC-derived secretomes in neonatal care: Focus on BPD and NEC. Stem Cell Research & Therapy,16, Article 476.","journal-title":"Stem Cell Research & Therapy"},{"key":"11236_CR6","first-page":"1","volume":"7","author":"H BAHARLOOI","year":"2023","unstructured":"Baharlooi, H., Pournazari, M., Assar, S., & Soufivand, P. (2023). Immunosenescence of Mesenchymal Stem Cells and Autoimmune Diseases; the Dark Side of Immune System. Rheumatology Research, 7, 1\u201312.","journal-title":"Rheumatology Research"},{"key":"11236_CR7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M BROWN","year":"2019","unstructured":"Brown, M., & O\u2019reilly, S. (2019). The immunopathogenesis of fibrosis in systemic sclerosis. Clinical And Experimental Immunology, 195, 310\u2013321.","journal-title":"Clinical And Experimental Immunology"},{"key":"11236_CR8","doi-asserted-by":"crossref","unstructured":"Burk, J., Sassmann, A., Kasper, C., Nimptsch, A. & Schubert, S. (2022). Extracellular Matrix Synthesis and Remodeling by Mesenchymal Stromal Cells Is Context-Sensitive. Int J Mol Sci, 23.","DOI":"10.3390\/ijms23031758"},{"key":"11236_CR9","doi-asserted-by":"crossref","first-page":"107300","DOI":"10.1016\/j.jbc.2024.107300","volume":"300","author":"JF CALVER","year":"2024","unstructured":"Calver, J. F., Parmar, N. R., Harris, G., Lithgo, R. M., Stylianou, P., Zetterberg, F. R., Gooptu, B., Mackinnon, A. C., Carr, S. B., Borthwick, L. A., Scott, D. J., Stewart, I. D., Slack, R. J., Jenkins, R. G., & John, A. E. (2024). Defining the mechanism of galectin-3-mediated TGF-beta1 activation and its role in lung fibrosis. Journal Of Biological Chemistry,300, 107300.","journal-title":"Journal Of Biological Chemistry"},{"key":"11236_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jare.2024.05.004","volume":"70","author":"MT CATARINA","year":"2025","unstructured":"Catarina, M. T., S\u00e9rgio, J. O. A. N. A. S. R., Susana, P. C., S., & Joana, P. M. (2025). Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? Journal of Advanced Research, 70, 103\u2013124.","journal-title":"Journal of Advanced Research"},{"key":"11236_CR11","doi-asserted-by":"crossref","first-page":"2001689","DOI":"10.1002\/adhm.202001689","volume":"10","author":"C CHANG","year":"2021","unstructured":"Chang, C., Yao, Y. A. N. J., Zhang, Z., Li, C., X., & Mao, H. Q. (2021). Effects of mesenchymal stem cell-derived paracrine signals and their delivery strategies. Advanced healthcare materials, 10, 2001689.","journal-title":"Advanced Healthcare Materials"},{"key":"11236_CR12","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhu, H., Zhang, Y., & & Liu, M. (2026). Mesenchymal stromal cells ameliorate systemic sclerosis-interstitial lung disease via PD-1\/PD-L1 signalling axis. 12.","DOI":"10.1136\/rmdopen-2025-006324"},{"key":"11236_CR13","doi-asserted-by":"crossref","unstructured":"Colic, J., Pruner, I., Damjanov, N., Antovic, J., Sefik-Bukilica, M., Cerinic, M. M. & Antovic, A. (2025). Circulating extracellular vesicles as predictive biomarkers of progressive interstitial lung disease in systemic sclerosis\u2014a prospective cohort study. Frontiers in Medicine, Volume 12\u20132025.","DOI":"10.3389\/fmed.2025.1594201"},{"key":"11236_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.63032\/YHBL8967","volume":"3","author":"E Costa","year":"2024","unstructured":"Costa, E., Cunha-Santos, F., Dourado, E., Oliveira, D., Falzon, L., Rom\u00e3o, V., Duarte, A. C., Cordeiro, A., Santiago, T., & Sepriano, A. (2024). Systematic literature review to inform the Portuguese recommendations for the management of Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases. ARP Rheumatology,3, 128\u2013144.","journal-title":"ARP Rheumatology"},{"key":"11236_CR15","doi-asserted-by":"crossref","unstructured":"Courvoisier, D. S., Russo, B., Chiric\u0103, I. S., & Iudici, M. (2026). Screening failure in systemic sclerosis randomized trials: reporting, rates, causes, and trends over time. Rheumatology Advances in Practice, rkag018.","DOI":"10.1093\/rap\/rkag018"},{"key":"11236_CR16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/rheumatology\/keab584","volume":"61","author":"A Daumas","year":"2022","unstructured":"Daumas, A., Magalon, J., Jouve, E., Casanova, D., Philandrianos, C., Abellan Lopez, M., Mallet, S., Veran, J., Auquit-Auckbur, I., Farge, D., Levesque, H., Benhamou, Y., Arnaud, L., Giraudo, L., Dumoulin, C., Giverne, C., Boyer, O., Giuliani, A., Bourgarel, V., \u2026 Pers, Y. M. (2022). Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: A multicentre randomized trial autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology (Oxford, England),61, 1936\u20131947.","journal-title":"Rheumatology (Oxford, England)"},{"key":"11236_CR17","doi-asserted-by":"crossref","unstructured":"Del Galdo, F., Lescoat, A., Conaghan, P. G., Bertoldo, E., \u010coli\u0107, J., Santiago, T., Suliman, Y. A., Matucci-Cerinic, M., Gabrielli, A., Distler, O., Hoffmann-Vold, A.-m., Castellv\u00ed, I., Balbir-gurman, A., Vonk, M., Ananyeva, L., Rednic, S., Tarasova, A., Ostojic, P., Boyadzhieva, V., El Aoufy, K., Farrington, S., Galetti, I., Denton, C. P., Kowal-bielecka, O., Mueller-Ladner, U. & Allanore, Y. (2024). EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Annals of the Rheumatic Diseases, ard-2024-226430.","DOI":"10.1136\/ard-2024-226430"},{"key":"11236_CR18","doi-asserted-by":"crossref","unstructured":"Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C. & He, J. (2024). TGF-\u03b2 signaling in health, disease and therapeutics. Signal Transduction and Targeted Therapy, 9, 61.","DOI":"10.1038\/s41392-024-01764-w"},{"key":"11236_CR19","doi-asserted-by":"crossref","unstructured":"Denton, C. P., & De Lorenzis, E. (2024). The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary. 63, 2948\u20132955.","DOI":"10.1093\/rheumatology\/keae390"},{"key":"11236_CR20","volume":"12","author":"X Di","year":"2025","unstructured":"Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2025). Targeting fibrosis: From molecular mechanisms to advanced therapies. Advanced Science,12, Article 2410416.","journal-title":"Advanced Science"},{"key":"11236_CR21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., & Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy,8, 315\u2013317.","journal-title":"Cytotherapy"},{"key":"11236_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"RV ELIZABETH","year":"2023","unstructured":"Elizabeth, R. V., Kristofer, A., & Vanessa, S. (2023). Systemic sclerosis. The Lancet, 401, 304\u2013318.","journal-title":"The Lancet"},{"key":"11236_CR23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.reth.2025.04.014","volume":"29","author":"F ELMI","year":"2025","unstructured":"Elmi, F., Soltanmohammadi, F., Fayeghi, T., Farajnia, S., & Alizadeh, E. (2025). Preventing MSC aging and enhancing immunomodulation: Novel strategies for cell-based therapies. Regen Ther, 29, 517\u2013539.","journal-title":"Regen Ther"},{"key":"11236_CR24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022). Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nature Reviews Rheumatology,18, 683\u2013693.","journal-title":"Nature Reviews Rheumatology"},{"key":"11236_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102755","volume":"20","author":"D Farge","year":"2021","unstructured":"Farge, D., Loisel, S., Lansiaux, P., & Tarte, K. (2021). Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmunity Reviews,20, Article 102755.","journal-title":"Autoimmunity Reviews"},{"key":"11236_CR26","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","volume":"4","author":"D Farge","year":"2022","unstructured":"Farge, D., Loisel, S., Resche-Rigon, M., Lansiaux, P., Colmegna, I., Langlais, D., Charles, C., Pugnet, G., Maria, A. T. J., Chatelus, E., Martin, T., Hachulla, E., Kheav, V. D., Lambert, N. C., Wang, H., Michonneau, D., Martinaud, C., Senseb\u00e9, L., Cras, A., & Tarte, K. (2022). Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: A single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study. The Lancet Rheumatology,4, e91\u2013e104.","journal-title":"The Lancet Rheumatology"},{"key":"11236_CR27","unstructured":"Food and Drug Administration (2023). Potency assurance for cellular and gene therapy products: guidance for industry."},{"key":"11236_CR28","doi-asserted-by":"crossref","unstructured":"Ganesan, N., Chang, Y. D., Hung, S. C., Lan, J. L., Liao, J. W., Fu, S. T. & Lee, C. C. (2023). Mesenchymal stem cells suppressed skin and lung inflammation and fibrosis in topoisomerase I-induced systemic sclerosis associated with lung disease mouse model. 391, 323\u2013337.","DOI":"10.1007\/s00441-022-03716-8"},{"key":"11236_CR29","doi-asserted-by":"crossref","unstructured":"Gong, P., Ding, Y., Sun, R., Jiang, Z., Li, W., Su, X., Tian, R., Zhou, Y., Wang, T., Jiang, J. & Li, P. (2022). Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages. 8, 466.","DOI":"10.1038\/s41420-022-01264-2"},{"key":"11236_CR30","volume":"10","author":"X Han","year":"2025","unstructured":"Han, X., Liao, R., Li, X., Zhang, C., Huo, S., Qin, L., Xiong, Y., He, T., Xiao, G., & Zhang, T. (2025). Mesenchymal stem cells in treating human diseases: Molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy,10, Article 262.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"11236_CR31","doi-asserted-by":"crossref","unstructured":"Henrique-Neto, \u00c1., Vasconcelos, M. Y. K., Dias, J. B. E., De Moraes, D. A., Gon\u00e7alves, M. S., Zanin-Silva, D. C., Zucoloto, T. G., De Oliveira, M. F. C., Dotoli, G. M., Weffort, L. F., Leopoldo, V. C. & Oliveira, M. C (2021). Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. Advances in Rheumatology, 61, 9.","DOI":"10.1186\/s42358-021-00166-8"},{"key":"11236_CR32","doi-asserted-by":"crossref","unstructured":"Hwang, W. L., Huang, S. W., Hsiao, A. C., Chen, C. Y., Hsu, K. F., Hsieh, Y. T. & Liao, T. T. (2025). Harnessing engineered mesenchymal stem cell-derived extracellular vesicles for innovative cancer treatments. Stem Cell Research & Therapy, 16, 648.","DOI":"10.1186\/s13287-025-04708-5"},{"key":"11236_CR33","doi-asserted-by":"crossref","unstructured":"Iglesias, M., Torre-Villalvazo, I., Butr\u00f3n-Gandarillas, P., Rodr\u00edguez-Reyna, T. S., Torre-Anaya, E. A. & Guevara-Cruz, M. (2023). Adipose derived stromal vascular fraction and fat graft for treating the hands of patients with systemic sclerosis. A randomized clinical trial. 18, e0289594.","DOI":"10.1371\/journal.pone.0289594"},{"key":"11236_CR34","doi-asserted-by":"crossref","first-page":"1551911","DOI":"10.3389\/fimmu.2025.1551911","volume":"16","author":"SA JIMENEZ","year":"2025","unstructured":"Jimenez, S. A., Mendoza, F. A., & Piera-velazquez, S. (2025). A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Frontiers in Immunology, 16, 1551911.","journal-title":"Frontiers in Immunology"},{"key":"11236_CR35","volume":"12","author":"J Jin","year":"2021","unstructured":"Jin, J., Ou, Q., Wang, Z., Tian, H., Xu, J.-Y., Gao, F., Hu, S., Chen, J., Wang, J., Zhang, J., Lu, L., Jin, C., Xu, G.-T., & Zhao, J. (2021). BMSC-derived extracellular vesicles intervened the pathogenic changes of scleroderma in mice through miRNAs. Stem Cell Research & Therapy,12, Article 327.","journal-title":"Stem Cell Research & Therapy"},{"key":"11236_CR36","doi-asserted-by":"crossref","DOI":"10.3390\/biom15121734","volume":"15","author":"D Kashirina","year":"2025","unstructured":"Kashirina, D., Matveeva, D., Ezdakova, M., Brzhozovskiy, A., Kononikhin, A., Pastushkova, L., Larina, I., Nikolaev, E., Buravkova, L., & Ratushnyy, A. (2025). Influence of stress-induced senescence on the secretome of primary mesenchymal stromal cells. Biomolecules,15, Article 1734.","journal-title":"Biomolecules"},{"key":"11236_CR37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/BOR.0000000000000959","volume":"35","author":"Y KAWAGUCHI","year":"2023","unstructured":"Kawaguchi, Y., & Kuwana, M. (2023). Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Current Opinion In Rheumatology, 35, 309\u2013316.","journal-title":"Current Opinion In Rheumatology"},{"key":"11236_CR38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","volume":"80","author":"D KHANNA","year":"2021","unstructured":"Khanna, D., Huang, S., Lin, C. J. F., & Spino, C. (2021). New composite endpoint in early diffuse cutaneous systemic sclerosis: Revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Annals Of The Rheumatic Diseases, 80, 641\u2013650.","journal-title":"Annals Of The Rheumatic Diseases"},{"key":"11236_CR39","doi-asserted-by":"crossref","unstructured":"Kizilay Mancini, O., Acevedo, M., Fazez, N., Cuillerier, A., Fernandez Ruiz, A., Huynh, D. N., Burelle, Y., Ferbeyre, G. & Baron, M. (2022). In M. Baron (Ed.), Oxidative stress-induced senescence mediates inflammatory and fibrotic phenotypes in fibroblasts from systemic sclerosis patients (Vol. 61, pp. 1265\u20131275).","DOI":"10.1093\/rheumatology\/keab477"},{"key":"11236_CR40","doi-asserted-by":"crossref","unstructured":"Ko, J., Noviani, M., Chellamuthu, V. R., Albani, S. & Low, A. H. L. (2023). The pathogenesis of systemic sclerosis: The origin of fibrosis and interlink with vasculopathy and autoimmunity. International Journal of Molecular Sciences, 24, 14287.","DOI":"10.3390\/ijms241814287"},{"key":"11236_CR41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1691988","volume":"16","author":"K Komura","year":"2025","unstructured":"Komura, K. (2025). The clinical utility of autoantibodies in systemic sclerosis: A review with a focus on cohort differences and standardization. Frontiers in Immunology,16, Article 1691988.","journal-title":"Frontiers in Immunology"},{"key":"11236_CR42","doi-asserted-by":"crossref","unstructured":"Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X. & Xu, X. (2022a). Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? 13, 580.","DOI":"10.1038\/s41419-022-05034-x"},{"key":"11236_CR43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-022-05034-x","volume":"13","author":"M KOU","year":"2022","unstructured":"Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., Yan, X., Wang, Y., Zhang, J., Xu, A., Tse, H. F., & Lian, Q. (2022b). Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: A next generation therapeutic tool? Cell Death & Disease, 13, 580.","journal-title":"Cell Death & Disease"},{"key":"11236_CR44","doi-asserted-by":"crossref","unstructured":"Krawczenko, A., & Klimczak, A. (2022). Adipose Tissue-Derived Mesenchymal Stem\/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration. 23.","DOI":"10.3390\/ijms23052425"},{"key":"11236_CR45","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., Al-Shabeeb Akil, A. S., Macha, M. A., Mir, R., & Bhat, A. A. (2024). Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduction and Targeted Therapy,9, Article 27.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"11236_CR46","doi-asserted-by":"crossref","unstructured":"Leah, A. M.-C. & Janet, A. W. E. (2024). Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review. Cryobiology, 115, 104856.","DOI":"10.1016\/j.cryobiol.2024.104856"},{"key":"11236_CR47","doi-asserted-by":"crossref","first-page":"151331","DOI":"10.1016\/j.ejcb.2023.151331","volume":"102","author":"SS LEE","year":"2023","unstructured":"Lee, S. S., V\u0169, T. T., Weiss, A. S., & Yeo, G. C. (2023). Stress-induced senescence in mesenchymal stem cells: Triggers, hallmarks, and current rejuvenation approaches. European Journal Of Cell Biology, 102, 151331.","journal-title":"European Journal Of Cell Biology"},{"key":"11236_CR48","first-page":"1911","volume":"40","author":"G Lepri","year":"2022","unstructured":"Lepri, G., Orlandi, M., Di Battista, M., De Mattia, G., Da Rio, M., Codullo, V., Guiducci, S., & Della Rossa, A. (2022). Systemic sclerosis: One year in review 2022. Clinical And Experimental Rheumatology, 40, 1911\u20131920.","journal-title":"Clinical And Experimental Rheumatology"},{"key":"11236_CR49","doi-asserted-by":"crossref","unstructured":"Leyla, B., Mohammad, J., Sheida, M., Bahareh Heshmat, G., Sadra, T., Fatemeh Davari, T., Mohammadhosein, R., Luca, C. & Shi, Z.\u00a0(2025). Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt\/\u03b2-catenin and TGF-\u03b2 signal transduction pathways as potential targets. European Journal of Pharmacology, 999, 177607.","DOI":"10.1016\/j.ejphar.2025.177607"},{"key":"11236_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jare.2022.05.012","volume":"45","author":"h Li","year":"2023","unstructured":"Li, H., Dai, H., & Li, J. (2023). Immunomodulatory properties of mesenchymal stromal\/stem cells: The link with metabolism. Journal Of Advanced Research, 45, 15\u201329.","journal-title":"Journal Of Advanced Research"},{"key":"11236_CR51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/scd.2021.0112","volume":"30","author":"M LI","year":"2021","unstructured":"Li, M., Zhang, H. P., Wang, X. Y., Chen, Z. G., Lin, X. F., & Zhu, W. (2021). Mesenchymal stem cell-derived exosomes ameliorate dermal fibrosis in a murine model of bleomycin-induced scleroderma. Stem Cells and Development, 30, 981\u2013990.","journal-title":"Stem Cells and Development"},{"key":"11236_CR52","doi-asserted-by":"crossref","unstructured":"Louay, Alexey, V. C., Olga, N. M., Mikhail, S. A. & Olga, N. T. (2026). The aging interactome: From cellular dysregulation to therapeutic frontiers in age-related diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872, 168060.","DOI":"10.1016\/j.bbadis.2025.168060"},{"key":"11236_CR53","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.ymthe.2025.02.003","volume":"33","author":"w Lu","year":"2025","unstructured":"Lu, W., & Allickson, J. (2025). Mesenchymal stromal cell therapy: Progress to date and future outlook. Molecular Therapy, 33, 2679\u20132688.","journal-title":"Molecular Therapy"},{"key":"11236_CR54","doi-asserted-by":"crossref","unstructured":"Ma, F., Tsou, P.-S., Gharaee-kermani, M., Plazyo, O., Xing, X., Kirma, J., Wasikowski, R., Hile, G. A., Harms, P. W., Jiang, Y., Xing, E., Nakamura, M., Ochocki, D., Brodie, W. D., Pillai, S., Maverakis, E., Pellegrini, M., Modlin, R. L., Varga, J., Tsoi, L. C., Lafyatis, R., Kahlenberg, J. M., Billi, A. C., Khanna, D. & Gudjonsson, J. E. (2024). Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis. Nature Communications, 15, 210.","DOI":"10.1038\/s41467-023-44645-6"},{"key":"11236_CR55","doi-asserted-by":"crossref","unstructured":"Maciejewska, M., & Sikora, M. (2022). Raynaud\u2019s Phenomenon with Focus on Systemic Sclerosis. 11.","DOI":"10.3390\/jcm11092490"},{"key":"11236_CR56","doi-asserted-by":"crossref","unstructured":"Mao, J., Zhou, L. I. U. J., Wang, M., Xiong, G., X., & Deng, Y. (2022). Hypoxia-induced interstitial transformation of microvascular endothelial cells by mediating HIF-1\u03b1\/VEGF signaling in systemic sclerosis. 17, e0263369.","DOI":"10.1371\/journal.pone.0263369"},{"key":"11236_CR57","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.7150\/ijms.115650","volume":"22","author":"q Meng","year":"2025","unstructured":"Meng, Q., Zheng, Y., Chen, X., Li, M. U. J., Gao, C., Liu, Y., W., & Wang, Y. (2025). Mesenchymal Stem Cells Senescence: Mechanism and Rejuvenation Interventions. International Journal Of Medical Sciences, 22, 3692\u20133708.","journal-title":"International Journal Of Medical Sciences"},{"key":"11236_CR58","doi-asserted-by":"crossref","unstructured":"Mizenko, R. R., Feaver, M., Bozkurt, B. T., & Lowe, N (2024). A critical systematic review of extracellular vesicle clinical trials 13, e12510.","DOI":"10.1002\/jev2.12510"},{"key":"11236_CR59","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3390\/ijms24032963","volume":"24","author":"JE MOUAWAD","year":"2023","unstructured":"Mouawad, J. E., & Feghali-Bostwick, C. (2023). The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis. International Journal of Molecular Sciences, 24, 2963.","journal-title":"International Journal of Molecular Sciences"},{"key":"11236_CR60","doi-asserted-by":"crossref","unstructured":"Munoz-Perez, E., & Gonzalez-Pujana, A. (2021). Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues. 13.","DOI":"10.3390\/pharmaceutics13111802"},{"key":"11236_CR61","first-page":"100790","volume":"35","author":"A MUNTYANU","year":"2024","unstructured":"Muntyanu, A., Aw, K., Kaouache, M., Rahme, E., Osman, M., Baron, M., Ghazal, S., & Netchiporouk, E. (2024). Epidemiology of systemic sclerosis in Quebec, Canada: A population-based study. Lancet Reg Health Am, 35, 100790.","journal-title":"Lancet Reg Health Am"},{"key":"11236_CR62","doi-asserted-by":"crossref","first-page":"1635809","DOI":"10.3389\/fmicb.2025.1635809","volume":"16","author":"B NI","year":"2025","unstructured":"Ni, B., Gong, Y., Li, B., Qiu, L., He, K., Guo, J., Fang, H., Gao, M., Chen, M., Wei, C., Sun, W., Liu, B., Li, M., Wang, S., & Xu, L. (2025). Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis. Frontiers In Microbiology, 16, 1635809.","journal-title":"Frontiers In Microbiology"},{"key":"11236_CR63","unstructured":"OpenAI (2026a). ChatGPT generated image created using the prompt: \u2018Create a detailed scientific graphical abstract style flowchart illustrating the role of myofibroblasts and mesenchymal stem cells (MSCs) in fibrosis following tissue injury. Show injury activating bone marrow derived fibrocytes and monocytes and parenchymal tissue cells including endothelial cells, epithelial cells, pericytes and adipocytes. Include fibroblast activation mediated by TGF beta and ROS signaling leading to myofibroblast differentiation, contractility and matrix production. Depict signaling pathways such as CXCR4, CXCL12, hypoxia, Wnt and Notch contributing to cellular plasticity. Show increased ECM deposition, collagen cross linking and matrix remodeling progressing toward fibrosis. Include MSC mediated antifibrotic effects such as secretion of matrix metalloproteinases, inhibition of profibrotic growth factors including TGF beta, suppression of fibroblast activation, inhibition of collagen synthesis and stimulation of ECM breakdown. Use labeled arrows, stepwise interactions, color coded sections and a clean professional biomedical illustration style suitable for publication in a review article\u2019."},{"key":"11236_CR64","unstructured":"OpenAI (2026b). ChatGPT generated image created using the prompt: Create a scientific infographic illustrating the therapeutic mechanisms of mesenchymal stem cells (MSCs) in a human patient. On the left side, show mesenchymal stem cells inside a circular boundary labeled \u2018Mesenchymal stem cells\u2019, with an arrow pointing toward a human body silhouette labeled \u2018to patient\u2019. From the patient, create three directional arrows leading to three therapeutic effect panels on the right side.\u00a0The first panel should be labeled \u2018Immunomodulation\u2019 and include bullet points: Secretion of cytokines, Anti-inflammatory effects, Immune cell regulation, with an illustrative lung or immune-related organ graphic. The second panel should be labeled \u2018Anti-fibrotic effects\u2019 with bullet points: Decrease fibrosis, Reduce scarring, accompanied by an illustration of fibrotic lung or kidney tissue improving. The third panel should be labeled \u2018Pro-angiogenic effects\u2019 with bullet points: Promote blood vessel formation, Enhance tissue healing, with a visual of new blood vessel formation in tissue. Use a clean medical illustration style with soft gradients, pastel colors, and clear arrows to visually explain MSC-based therapy mechanisms in systemic sclerosis."},{"key":"11236_CR65","unstructured":"OpenAI 2026c generated using prompt,\u2018Create a high-quality scientific graphical abstract style digital illustration showing mesenchymal stem cells (MSCs) releasing extracellular vesicles (EVs) through paracrine signaling mechanisms. Depict exosomes and microvesicles being secreted from MSCs, containing bioactive cargo such as proteins, lipids, and microRNAs. Show arrows from EVs interacting with three target cell types including immune cells, fibroblasts, and endothelial cells. Include therapeutic effects such as angiogenesis, anti-fibrotic activity, and immunomodulation. Use a clean biomedical infographic layout with labeled components, soft pastel scientific color palette, subtle gradients, and minimal background noise suitable for inclusion in a peer-reviewed review article on MSC therapy in systemic sclerosis. Add text labels such as MSCs release extracellular vesicles, EVs contain cargo: proteins, lipids, miRNAs, and highlight potential therapeutic effects. The overall style should resemble a professional graphical abstract for publication in a biomedical journal.\u2018."},{"key":"11236_CR66","doi-asserted-by":"crossref","unstructured":"Pang, J. L., Shao, H., Xu, X. G., Lin, Z. W., Chen, X.-Y., Chen, J.-Y., Mou, X.-Z., & Hu, P. Y. (2024). Targeted drug delivery of engineered mesenchymal stem\/stromal-cell-derived exosomes in cardiovascular disease: recent trends and future perspectives. Frontiers in Bioengineering and Biotechnology, Volume 12\u20132024.","DOI":"10.3389\/fbioe.2024.1363742"},{"key":"11236_CR67","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/biomedicines10020316","volume":"10","author":"TI PAPADIMITRIOU","year":"2022","unstructured":"Papadimitriou, T. I., Van Caam, A., Van Der Kraan, P. M., & Thurlings, R. M. (2022). Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. Biomedicines, 10, 316.","journal-title":"Biomedicines"},{"key":"11236_CR68","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/cells13181519","volume":"13","author":"KA PAPAVASSILIOU","year":"2024","unstructured":"Papavassiliou, K. A., Sofianidi, A. A., Spiliopoulos, F. G., Gogou, V. A., Gargalionis, A. N., & Papavassiliou, A. G. (2024). YAP\/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis. Cells, 13, 1519.","journal-title":"Cells"},{"key":"11236_CR69","volume":"9","author":"Y Park","year":"2020","unstructured":"Park, Y., Lee, Y. J., Koh, J. H., Lee, J., Min, H.-K., Kim, M. Y., Kim, K. J., Lee, S. J., Rhie, J. W., Kim, W.-U., Park, S.-H., Moon, S.-H., & Kwok, S.-K. (2020). Clinical efficacy and safety of injection of stromal vascular fraction derived from autologous adipose tissues in systemic sclerosis patients with hand disability: A proof-of-concept trial. Journal of Clinical Medicine,9, Article 3023.","journal-title":"Journal of Clinical Medicine"},{"key":"11236_CR70","volume":"24","author":"E Patnaik","year":"2023","unstructured":"Patnaik, E., Lyons, M., Tran, K., & Pattanaik, D. (2023). Endothelial dysfunction in systemic sclerosis. International Journal of Molecular Sciences,24, Article 14385.","journal-title":"International Journal of Molecular Sciences"},{"key":"11236_CR71","doi-asserted-by":"crossref","unstructured":"Pauline, R., Marie, M., Alexandre Thibault Jacques, M., Karine, T., Jos\u00e9phine, L.-k.-h., Christian, J., Philippe, G. & Dani\u00e8le, N.\u00a0(2021). Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p. Journal of Autoimmunity, 121, 102660.","DOI":"10.1016\/j.jaut.2021.102660"},{"key":"11236_CR72","doi-asserted-by":"crossref","unstructured":"Rozier, P., Maumus, M., Bony, C., Maria, A. T. J., Sabatier, F., Jorgensen, C., Guilpain, P. & No\u00ebl, D. (2021a). Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis. 22.","DOI":"10.3390\/ijms22136837"},{"key":"11236_CR73","doi-asserted-by":"crossref","unstructured":"Rozier, P., Maumus, M., Maria, A. T. J., Toupet, K., Jorgensen, C. & Guilpain, P. (2021b). Lung Fibrosis Is Improved by Extracellular Vesicles from IFN\u03b3-Primed Mesenchymal Stromal Cells in Murine Systemic Sclerosis. 10.","DOI":"10.3390\/cells10102727"},{"key":"11236_CR74","doi-asserted-by":"crossref","unstructured":"Rozier, P., Maumus, M., Maria, A. T. J., Toupet, K., Lai-Kee-Him, J., Jorgensen, C., Guilpain, P. & No\u00ebl, D. (2021c). Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p. Journal Of Autoimmunity, 121, 102660.","DOI":"10.1016\/j.jaut.2021.102660"},{"key":"11236_CR75","doi-asserted-by":"crossref","unstructured":"Russo, B., Chirica, I. S., Courvoisier, D. S. & Iudici, M.\u00a0(2025). Trial-level factors affecting accrual rate of systemic sclerosis randomized clinical trials. Seminars In Arthritis And Rheumatism, 73, 152749.","DOI":"10.1016\/j.semarthrit.2025.152749"},{"key":"11236_CR76","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/life12091332","volume":"12","author":"H SAFWAN-ZAITER","year":"2022","unstructured":"Safwan-Zaiter, H., Wagner, N., & Wagner, K. D. (2022). P16INK4A\u2014More Than a Senescence Marker. Life, 12, 1332.","journal-title":"Life"},{"key":"11236_CR77","volume-title":"Diseases of the Chest, Heart and Vascular System 2025\u20132028: Diagnostic Imaging","author":"C Schaefer-Prokop","year":"2025","unstructured":"Schaefer-Prokop, C., & Pompe, E. (2025). Pulmonary Manifestations of Systemic Diseases. In J. Hodler, R. A. Kubik-Huch, & J. E. Roos (Eds.), Diseases of the Chest, Heart and Vascular System 2025\u20132028: Diagnostic Imaging. Springer Nature Switzerland."},{"key":"11236_CR78","doi-asserted-by":"crossref","unstructured":"Siraj, Y., Galderisi, U., & Alessio, N. (2023). Senescence induces fundamental changes in the secretome of mesenchymal stromal cells (MSCs): implications for the therapeutic use of MSCs and their derivates. Frontiers in Bioengineering and Biotechnology, Volume 11\u20132023.","DOI":"10.3389\/fbioe.2023.1148761"},{"key":"11236_CR79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4078\/jrd.2024.0129","volume":"32","author":"HH SON","year":"2025","unstructured":"Son, H. H., & Moon, S. J. (2025). Pathogenesis of systemic sclerosis: An integrative review of recent advances. Journal of rheumatic diseases, 32, 89\u2013104.","journal-title":"Journal of rheumatic diseases"},{"key":"11236_CR80","doi-asserted-by":"crossref","unstructured":"Sowmya, V., Katarina Le, B., Rachele, C., Georges, D., Anthony, J. F., Jacques, G., Mauro, K., Lena, K., Manoj, M. L., Jan, N., Viviana, M., Yufang, S., Karin, T., Daniel, J. W. & Ivan, M.\u00a0(2023). An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization\/Technical Committee 276 Biobanking Standards for bone marrow-MSCs and umbilical cord tissue\u2013derived MSCs for research purposes. Cytotherapy, 25, 803\u2013807.","DOI":"10.1016\/j.jcyt.2023.04.005"},{"key":"11236_CR81","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13075-022-02915-6","volume":"24","author":"T SUZUKA","year":"2022","unstructured":"Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022). Therapeutic effects of adipose-derived mesenchymal stem\/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. Arthritis Res Ther, 24, 228.","journal-title":"Arthritis Res Ther"},{"key":"11236_CR82","doi-asserted-by":"crossref","unstructured":"Sykorova, S., Krivy, J., Hadova, K., Kekelakova, A., Vavrinec, P. & Vavrincova-yaghi, D. (2026). Kynurenic acid as a promising therapeutic agent in renal fibrosis: Dual modulation of fibrosis and immune crosstalk. British Journal of Pharmacology, 183, 4448\u20134470.","DOI":"10.1111\/bph.70469"},{"key":"11236_CR83","doi-asserted-by":"crossref","unstructured":"Teegala, L. R., Gudneppanavar, R., Sabu Kattuman, E. E., Snyderman, M., Thanusha, A. V., Katari, V., Thodeti, C. K. & Paruchuri, S. (2023). Prostaglandin E2 attenuates lung fibroblast differentiation via inactivation of yes-associated protein signaling. The FASEB Journal, 37, e23199.","DOI":"10.1096\/fj.202300745RR"},{"key":"11236_CR84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13287-025-04431-1","volume":"16","author":"C WANG","year":"2025","unstructured":"Wang, C., Wu, Y., & Jiang, J. (2025a). The role and mechanism of mesenchymal stem cells in immunomodulation of type 1 diabetes mellitus and its complications: Recent research progress and challenges: A review. Stem Cell Research & Therapy, 16, 308.","journal-title":"Stem Cell Research & Therapy"},{"key":"11236_CR85","doi-asserted-by":"crossref","first-page":"1492821","DOI":"10.3389\/fcell.2024.1492821","volume":"12","author":"X WANG","year":"2024","unstructured":"Wang, X., Guo, J., & Dai, Q. (2024). Mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis: Role and therapeutic directions. Front Cell Dev Biol, 12, 1492821.","journal-title":"Front Cell Dev Biol"},{"key":"11236_CR86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13287-025-04470-8","volume":"16","author":"Z WANG","year":"2025","unstructured":"Wang, Z., Shi, M., Liu, Z., Chen, Y., Shi, X., & Wang, J. (2025b). The stromal vascular fraction mitigates bleomycin-induced skin fibrosis in mice by modulating vascular lesions and secreting antifibrotic factors at different stages of disease. Stem Cell Research & Therapy, 16, 328.","journal-title":"Stem Cell Research & Therapy"},{"key":"11236_CR87","doi-asserted-by":"crossref","unstructured":"Weng, Z., Wang, Y., Ouchi, T., Liu, H., Qiao, X., Wu, C., Zhao, Z., Li, L., & Li, B. (2022). Mesenchymal Stem\/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies. 11, 356\u2013371.","DOI":"10.1093\/stcltm\/szac004"},{"key":"11236_CR88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdermsci.2022.07.009","volume":"107","author":"X Wu","year":"2022","unstructured":"Wu, X., Ming, B., Wu, T., Gao, R., Hu, P., Tang, J., Zhong, J., Zheng, F., & Dong, L. (2022). IL-33\/ST2 axis contributes to the dermal fibrosis of systemic sclerosis via promoting fibroblasts activation. Journal of Dermatological Science,107, 95\u2013104.","journal-title":"Journal of Dermatological Science"},{"key":"11236_CR89","unstructured":"Wu, Y., Ding, S., & Wang, D. & Sun, L. (n.d.).\u00a0RMD Open."},{"key":"11236_CR90","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1038\/s41598-024-72630-6","volume":"15","author":"Y XIAO","year":"2025","unstructured":"Xiao, Y., Xiang, Q., Wang, Y., Huang, Z., Yang, J., Zhang, X., Zhu, X., Xue, Y., Wan, W., Zou, H., & Yang, X. (2025a). Exosomes carrying adipose mesenchymal stem cells function alleviate scleroderma skin fibrosis by inhibiting the TGF-\u03b21\/Smad3 axis. Scientific Reports, 15, 7162.","journal-title":"Scientific Reports"},{"key":"11236_CR91","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1038\/s41598-024-72630-6","volume":"15","author":"Y XIAO","year":"2025","unstructured":"Xiao, Y., Xiang, Q., Wang, Y., Huang, Z., Yang, J., Zhang, X., Zhu, X., Xue, Y., Wan, W., Zou, H., & Yang, X. (2025b). Exosomes carrying adipose mesenchymal stem cells function alleviate scleroderma skin fibrosis by inhibiting the TGF-\u03b21\/Smad3 axis. Scientific Reports, 15, 7162.","journal-title":"Scientific Reports"},{"key":"11236_CR92","doi-asserted-by":"crossref","unstructured":"Xu, Q., Hou, W., Zhao, B., Fan, P., Wang, S., Wang, L. & Gao, J.\u00a0(2024). Mesenchymal stem cells lineage and their role in disease development. 30, 207.","DOI":"10.1186\/s10020-024-00967-9"},{"key":"11236_CR93","doi-asserted-by":"crossref","unstructured":"Yuan, W., Liu, M., Yang, D., Shi, Y., Wang, Z., Cao, X., Liang, J., Geng, L., Zhang, H., Feng, X., Jin, Z., Wang, D. & Sun, L.\u00a0(2025). Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: A propensity score-matched cohort study. Stem Cell Research & Therapy, 16, 128.","DOI":"10.1186\/s13287-025-04237-1"},{"key":"11236_CR94","doi-asserted-by":"crossref","unstructured":"Zaripova, L. N., Midgley, A., Christmas, S. E., Beresford, M. W., Pain, C., Baildam, E. M. & Oldershaw, R. A. (2023). Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases. 24.","DOI":"10.3390\/ijms242216040"},{"key":"11236_CR95","volume":"19","author":"H Zhang","year":"2017","unstructured":"Zhang, H., Liang, J., Tang, X., Wang, D., Feng, X., Wang, F., Hua, B., Wang, H., & Sun, L. (2017). Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Research & Therapy,19, Article 165.","journal-title":"Arthritis Research & Therapy"},{"key":"11236_CR96","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yang, Y., Gao, X., Gao, W. & Zhang, L (2023).Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis. Frontiers in Pharmacology, 14.","DOI":"10.3389\/fphar.2023.1263839"},{"key":"11236_CR97","doi-asserted-by":"crossref","unstructured":"Zhao, K., Kong, C., Shi, N., Jiang, J., & Li, P. (2023). Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis. Frontiers in Immunology, Volume 14\u20132023.","DOI":"10.3389\/fimmu.2023.1125257"},{"key":"11236_CR98","doi-asserted-by":"crossref","unstructured":"Zi-Ming, L., Jie-Yu, X., Song-Lu, T., Tian-Hao, L.,\u00a0Li-Quan, W., Lin, K., Jiu-Zuo, H., Nan-Ze, Y. & Xiao, L.\u00a0(2025). A novel microneedle-based delivery of NRF2-overexpressing exosomes for scleroderma therapy. International Journal of Biological Macromolecules, 334, 148450.","DOI":"10.1016\/j.ijbiomac.2025.148450"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11236-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:03:52Z","timestamp":1793300632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11236"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11236-z","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors acknowledge the use of artificial intelligence tools, including ChatGPT (OpenAI) and FigureLabs AI, to generate graphical elements and figures. All AI generated images were critically reviewed, edited, and validated by the authors to ensure scientific accuracy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical trial number: not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}